ANDA 204057, held by Glenmark Speclt. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 204057 (Norgestimate And Ethinyl Estradiol), held by Glenmark Speclt, was first approved by FDA on Feb 23, 2016, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 4, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 23, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters